Medivir AB announced the initiation of a Phase 2a trial in chronic genotype 1 hepatitis C infected patients to evaluate the efficacy, safety and tolerability of a 12-week combination therapy of simeprevir, TMC647055 and JNJ56914845, a NS5A replication complex inhibitor.
Taking the breast cancer drug anastrozole for five years reduced the chances of post-menopausal...
The Medicines Patent Pool and Bristol-Myers Squibb have signed a licensing agreement to increase...
Roche and Prothena Corp. plc have entered into a worldwide collaboration to develop and...
British Prime Minister David Cameron says he hopes to kick-start an international effort to find a cure or effective treatment for dementia by 2025, declaring that discovering a cure or treatment for dementia is "within our grasp."
Understanding the science behind pain, from a simple “ouch” to the chronic and excruciating, has been an elusive goal for centuries. But now, researchers are reporting a promising step toward studying pain in action, which could result in better ways to relieve pain and monitor healing.
A new £3 million Dementia Consortium has been launched to expedite development of new drugs for dementia. The Dementia Consortium unites the charity Alzheimer’s Research UK with life science technology transfer experts MRC Technology and pharmaceutical companies Eisai and Lilly.
The U.S. FDA today is implementing a plan to help phase out the use of medically important antimicrobials in food animals for food production purposes, such as to enhance growth or improve feed efficiency. So what's the plan? Find out...
GlaxoSmithKline (GSK) today announced a series of investments totaling approximately £200 million that will support the delivery of the company’s pipeline of new medicines and create a center for pharmaceutical manufacturing innovation in the UK.
Researchers have determined the structure of the rubella virus capsid protein, which is central to the virus's ability to assemble into an infectious particle and to infect humans. Could this discovery aid the development of drugs for other RNA viruses for which there are no therapeutic treatments? Find out...
Novartis Pharmaceuticals UK Limited has announced the launch of the UK’s largest clinical trial to investigate a potential new biologic treatment for adults with moderate-severe psoriasis.
New data analyses show that Boehringer-Ingelheim's Pradaxa was consistent in a wide range of patients with acute deep vein thrombosis, a blood clot in the leg veins, or pulmonary embolism, a blood clot in the lung, regardless of age, renal function, simultaneous use of NSAIDs or low-dose ASA or the presence of cancer.
Daiichi Sankyo Co. Ltd. announced results of the Phase 3 Hokusai-VTE study, where patients with either a history of cancer or with active cancer treated with the once-daily factor Xa-inhibitor edoxaban had a lower incidence of recurrent symptomatic venous thromboembolism (VTE) compared to warfarin.
Adding bortezomib to standard preventive therapy for graft-versus-host-disease results in improved outcomes for patients receiving stem cell transplants from mismatched and unrelated donors, according to new research.
Researchers are one step closer to an eye drop-free reality with the development of a drug-eluting contact lens designed for prolonged delivery of latanoprost, a common drug used for the treatment of glaucoma.
Researchers have successfully converted polyethylene terephthalate (PET), which is widely used to make plastic bottles, into a non-toxic biocompatible material with superior fungal killing properties.
Princeton University has announced that a vaccination program with Novartis meningococcal serogroup B (MenB) vaccine, Bexsero (Meningococcal Group B Vaccine), began today following a campus outbreak that has affected at least eight students.
Millennium: The Takeda Oncology Co., together with Takeda Pharmaceutical Co. Ltd., announced results from a retrospective, subgroup analysis of the Phase 3 VISTA study that showed a higher cumulative dose of Velcade suggests improved overall survival in previously untreated patients with multiple myeloma.
In one of the biggest advances against leukemia and other blood cancers in many years, doctors are reporting unprecedented success by using gene therapy to transform patients' blood cells into soldiers that seek and destroy cancer.
Researchers have discovered that certain combination drug therapies don't work well in clinical trials for cancer patients because one drug can make the other drug ineffective.
GlaxoSmithKline (GSK) announced the formation of the Oncology Clinical and Translational Consortium (OCTC), a collaborative scientific research network comprised of six internationally renowned comprehensive cancer centers.
A team of scientists has found that brain cancer cells resist therapy by dialing down the gene mutation targeted by drugs, then re-amplify that growth-promoting mutation after therapy has stopped.
Sanofi announced the results of a 24-week Phase 3b clinical study showing that Lyxumia met the primary endpoint of non-inferiority in blood sugar lowering when administered either before breakfast or the main meal of the day, indicate that lixisenatide works effectively at either time of administration.
Researchers have discovered how prostate cancer stem cells evolve as the disease progresses, a finding that could help point the way to more highly targeted therapies.
Three major cancer research centers have joined forces to launch Juno Therapeutics Inc., a new biotechnology company focused on novel immunotherapies for cancer. Juno is being launched with an initial investment of $120 million, making it one of the largest Series A biotech startups in history.
Roche and Molecular Partners AG have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular Partners’ DARPin biologics conjugated to toxic agents developed at Roche for the treatment of cancer.
A natural antibiotic turns out to be a lethal weapon in the fight against tuberculosis. So how does its unexpected dual action dramatically reduce the probability that bacteria that cause tuberculosis will become resistant? Find out...
Boehringer Ingelheim and Eli Lilly and Co. today announced new data from a Phase 4 study evaluating linagliptin as monotherapy and in combination with metformin in treatment-naive adults with newly diagnosed, uncontrolled Type 2 Diabetes.
- Page 1